Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 7, 2020
Product Development

Amgen’s adaptive solution to lupus

Amgen tackles clinical development challenges in lupus with an adaptive trial design
BioCentury | Oct 9, 2020
Translation in Brief

Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine

BioCentury’s roundup of translational news
BioCentury | Jan 3, 2019
Distillery Therapeutics

Transplant

BioCentury | Aug 24, 2018
Targets & Mechanisms

Computing checkpoints

Compugen takes the plunge into clinical development with a mAb against a new checkpoint
BioCentury | Jun 15, 2017
Tools & Techniques

Breaking the barrier

Companies are finally finding ways to develop cell-penetrating biologics
BioCentury | May 26, 2011
Distillery Therapeutics

Indication: Autoimmune disease

BioCentury | May 26, 2011
Distillery Therapeutics

Indication: Autoimmune disease

Items per page:
1 - 8 of 8